Medgend Icon


Suboxone FDA Approved Drugs

BUNAVAIL [Buprenorphine HydrochlorideC29H41NO4ClH : Naloxone HydrochlorideC19H21NO4ClH]
RX
-
eq 2.1mg base : eq 0.3mg base (buccal film)
eq 4.2mg base : eq 0.7mg base (buccal film)
eq 6.3mg base : eq 1mg base (buccal film)
BdsiJun 6, 2014
  • Maintenance treatment of opioid dependence.
  • Treatment of opioid dependence.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE [Buprenorphine HydrochlorideC29H41NO4ClH : Naloxone HydrochlorideC19H21NO4ClH]
RX
-
eq 2mg base : eq 0.5mg base (sublingual tablet)
eq 8mg base : eq 2mg base (sublingual tablet)
Actavis ElizabethFeb 22, 2013
Amneal PharmsFeb 22, 2013
Ethypharm Usa CorpOct 16, 2015
Kremers Urban PharmsSep 19, 2016
Sun Pharm Inds LtdAug 5, 2016
Teva Pharms UsaSep 8, 2014
West-ward Pharms IntJun 27, 2014
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SUBOXONE [Buprenorphine HydrochlorideC29H41NO4ClH : Naloxone HydrochlorideC19H21NO4ClH]
RX
-
eq 12mg base : eq 3mg base (buccal, sublingual film)
eq 2mg base : eq 0.5mg base (buccal, sublingual film)
eq 4mg base : eq 1mg base (buccal, sublingual film)
eq 8mg base : eq 2mg base (buccal, sublingual film)
Indivior IncAug 10, 2012
  • This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence.
  • Treatment of opioid dependence/sublingual or buccal application.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ZUBSOLV [Buprenorphine HydrochlorideC29H41NO4ClH : Naloxone HydrochlorideC19H21NO4ClH]
RX
-
eq 0.7mg base : eq 0.18mg base (sublingual tablet)
eq 1.4mg base : eq 0.36mg base (sublingual tablet)
eq 11.4mg base : eq 2.9mg base (sublingual tablet)
eq 2.9mg base : eq 0.71mg base (sublingual tablet)
eq 5.7mg base : eq 1.4mg base (sublingual tablet)
eq 8.6mg base : eq 2.1mg base (sublingual tablet)
Orexo Us IncOct 4, 2016
  • Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxone.
  • Sublingual administration of a pharmaceutical composition comprising buprenorphine.
  • Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.